PALO ALTO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the registration statement on Form S-4 (the “Registration Statement”), related to the previously announced proposed business combination (the “Business Combination”) between Denali Capital Acquisition Corp. ("Denali") (OTCB: DNQAF), a special purpose acquisition company, and Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex, has been declared effective by the U.S. Securities and Exchange Commission (the "SEC").
Related Questions
How will the effective registration on Form S‑4 affect Scilex’s (SCLX) share price in the short term?
What are the valuation metrics and implied premium for Denali Capital Acquisition Corp. (DNQAF) shareholders in the combined entity?
What is the expected timeline for closing the business combination and any associated regulatory approvals?
How will the merger impact Scilex’s capital structure, including potential dilution or leverage?
What are the projected financial synergies and revenue contributions from Semnur Pharmaceuticals post‑combination?
How does this transaction compare to recent SPAC‑based mergers in the biotech sector regarding pricing and market reception?
What are the key risks, such as integration challenges or clinical trial uncertainties, that could affect the combined company’s performance?
Will there be any changes to the management team or board composition after the merger, and how might that influence investor confidence?
How might the market’s perception of non‑opioid pain management assets influence the long‑term outlook for the combined entity?
What is the anticipated impact on liquidity and trading volume for both Scilex and Denali’s securities after the merger?